Vienna Versus SARS-CoV-2 Virus Study
- Conditions
- SARS-CoV-2COVID-19
- Interventions
- Diagnostic Test: Laboratory Analyses
- Registration Number
- NCT04407429
- Lead Sponsor
- Medical University of Vienna
- Brief Summary
This study examines the seroprevalence against SARS-CoV-2 in health care workers and patients at the Vienna General Hospital.
- Detailed Description
This study consists of 2 parts: a longitudinal study enrolling 3,000 health care professionals at the Vienna General Hospital testing their antibody status 6 times over a period of 12 months (Cohort A), and a serial cross-sectional study of 3,000 patients (i.e., a total of 9,000 patients) admitted to the Vienna General Hospital for non-COVID-19-related symptoms at 3 different time points during this pandemic (Cohort B).
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 12000
Inclusion Criteria
● Patients with available residual serum samples
Read More
Exclusion Criteria
● Serum samples from COVID-19 triage units at the Vienna General Hospital
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Patients Laboratory Analyses Patients admitted for non-COVID related symptoms to the Vienna General Hospital with available residual serum samples. Health care workers Laboratory Analyses Physicians, Nursing staff, Midwives, Medical-technical assistants (including medical, therapeutic and diagnostic healthcare staff, and medical and nursing assistants), administrative personnel with patient contact
- Primary Outcome Measures
Name Time Method Prevalence of antibody status in healthcare workers and in patients admitted for non-COVID-19 related symptoms over time 1 year
- Secondary Outcome Measures
Name Time Method Incidence rate of sero-conversion 1 year Identification of risk markers/factors for SARS-CoV-2 infection 1 year
Trial Locations
- Locations (1)
Medical University of Vienna
🇦🇹Vienna, Austria